Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Two-Component Disaggregation of ROE

Abiomed Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Mar 31, 2022 9.08% = 8.16% × 1.11
Mar 31, 2021 16.96% = 15.09% × 1.12
Mar 31, 2020 19.05% = 16.69% × 1.14
Mar 31, 2019 27.65% = 24.57% × 1.13
Mar 31, 2018 16.27% = 14.26% × 1.14
Mar 31, 2017 11.53% = 9.47% × 1.22

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The analysis of the Return on Equity (ROE) over the observed six-year period reveals a parabolic trajectory, characterized by a sharp increase peaking in 2019 followed by a sustained contraction through 2022.

Return on Equity (ROE)
ROE demonstrated significant growth between March 31, 2017, and March 31, 2019, rising from 11.53% to a peak of 27.65%. Subsequently, a downward trend emerged, with ROE falling to 19.05% in 2020, 16.96% in 2021, and ultimately reaching a period low of 9.08% by March 31, 2022.
Return on Assets (ROA)
The trajectory of ROA closely mirrors that of ROE, indicating a strong correlation. ROA increased from 9.47% in 2017 to a peak of 24.57% in 2019, before declining to 8.16% in 2022. The synchronicity between these two metrics suggests that the volatility in shareholder returns was primarily driven by changes in operational profitability or asset efficiency.
Financial Leverage
Financial leverage remained stable and relatively low throughout the period, moving from 1.22 in 2017 to 1.11 in 2022. The absence of significant volatility in this ratio indicates a conservative approach to debt and a consistent capital structure that did not change meaningfully over the six years.

The two-component disaggregation of ROE confirms that the fluctuations in equity returns were almost entirely attributable to the Return on Assets. Because the financial leverage ratio remained near unity and showed a slight downward trend, it played a negligible role in amplifying returns. Consequently, the decline in ROE observed from 2020 to 2022 is a direct reflection of the diminishing ROA, highlighting that the reduction in shareholder value was driven by asset performance rather than changes in financial gearing.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Three-Component Disaggregation of ROE

Abiomed Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Mar 31, 2022 9.08% = 13.23% × 0.62 × 1.11
Mar 31, 2021 16.96% = 26.61% × 0.57 × 1.12
Mar 31, 2020 19.05% = 24.14% × 0.69 × 1.14
Mar 31, 2019 27.65% = 33.66% × 0.73 × 1.13
Mar 31, 2018 16.27% = 18.89% × 0.76 × 1.14
Mar 31, 2017 11.53% = 11.70% × 0.81 × 1.22

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The Return on Equity (ROE) exhibited significant volatility between 2017 and 2022, characterized by a sharp increase to a peak in 2019 followed by a steady decline. The fluctuations in ROE were primarily driven by changes in profitability rather than shifts in asset efficiency or capital structure.

Net Profit Margin
A strong expansion in profitability was observed from 2017 to 2019, with the margin rising from 11.70% to a peak of 33.66%. This trend indicates a period of substantial growth in operational efficiency or pricing power. However, a subsequent contraction occurred, with the margin falling to 13.23% by 2022, serving as the primary catalyst for the overall decline in ROE.
Asset Turnover
A consistent downward trend in asset efficiency is evident over the analyzed period. The ratio declined from 0.81 in 2017 to 0.57 in 2021, before a marginal recovery to 0.62 in 2022. This pattern suggests that the company generated progressively lower revenue relative to its asset base throughout most of the period.
Financial Leverage
The financial leverage ratio remained remarkably stable, fluctuating within a tight range between 1.22 in 2017 and 1.11 in 2022. The lack of significant variance indicates that the company did not utilize increased debt to amplify its return on equity, maintaining a conservative and consistent capital structure.

The overall trajectory of the ROE reflects a compounding negative effect between 2019 and 2022. The simultaneous contraction of net profit margins and the general decline in asset turnover exerted downward pressure on returns. Because financial leverage remained nearly constant, there was no offset provided by financial gearing to mitigate the erosion of operational performance.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Five-Component Disaggregation of ROE

Abiomed Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Mar 31, 2022 9.08% = 0.72 × 1.00 × 18.47% × 0.62 × 1.11
Mar 31, 2021 16.96% = 0.78 × 1.00 × 34.01% × 0.57 × 1.12
Mar 31, 2020 19.05% = 0.79 × 1.00 × 30.54% × 0.69 × 1.14
Mar 31, 2019 27.65% = 0.98 × 1.00 × 34.23% × 0.73 × 1.13
Mar 31, 2018 16.27% = 0.70 × 1.00 × 27.07% × 0.76 × 1.14
Mar 31, 2017 11.53% = 0.57 × 1.00 × 20.59% × 0.81 × 1.22

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The Return on Equity (ROE) experienced significant volatility between 2017 and 2022, peaking at 27.65% in 2019 before declining to a period low of 9.08% in 2022. The trajectory of ROE was primarily driven by fluctuations in operating margins and tax burdens, as financial leverage and interest obligations remained relatively static.

Operating Profitability
The EBIT Margin showed a strong upward trend in the early part of the period, rising from 20.59% in 2017 to a peak of 34.23% in 2019. Although margins remained elevated through 2021, a substantial contraction occurred in 2022, with the margin dropping to 18.47%. This sharp decline in operational efficiency was the primary contributor to the erosion of ROE in the final year of the analysis.
Asset Utilization
Asset turnover exhibited a steady decline from 0.81 in 2017 to a low of 0.57 in 2021. This downward trend suggests that the company generated progressively less revenue per unit of asset. A slight recovery to 0.62 was observed in 2022, though it remained well below 2017 levels.
Tax and Interest Burdens
The interest burden remained constant at 1.00 throughout the entire period, indicating that interest expenses had no impact on the reduction of earnings. The tax burden was more volatile, increasing from 0.57 in 2017 to a peak of 0.98 in 2019, before trending downward to 0.72 by 2022.
Financial Leverage
Financial leverage remained stable and low, moving from 1.22 in 2017 to 1.11 in 2022. The lack of significant movement in this ratio indicates that the company did not utilize increased debt to amplify its return on equity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Two-Component Disaggregation of ROA

Abiomed Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Mar 31, 2022 8.16% = 13.23% × 0.62
Mar 31, 2021 15.09% = 26.61% × 0.57
Mar 31, 2020 16.69% = 24.14% × 0.69
Mar 31, 2019 24.57% = 33.66% × 0.73
Mar 31, 2018 14.26% = 18.89% × 0.76
Mar 31, 2017 9.47% = 11.70% × 0.81

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The Return on Assets (ROA) exhibited significant volatility between 2017 and 2022, peaking in 2019 before retreating to its lowest level of the period by 2022. The trajectory of ROA was primarily dictated by fluctuations in profitability rather than asset efficiency.

Net Profit Margin
Profitability experienced a sharp ascent from 11.70% in 2017 to a peak of 33.66% in 2019. Following this peak, margins remained relatively elevated, fluctuating between 24.14% and 26.61% during 2020 and 2021, before experiencing a significant contraction to 13.23% in 2022.
Asset Turnover
A consistent downward trend in asset utilization efficiency is observed from 2017 to 2021, with the ratio declining from 0.81 to 0.57. A marginal recovery to 0.62 was noted in 2022, although the ratio remained substantially lower than the 2017 baseline.
ROA Driver Analysis
The growth in ROA from 9.47% in 2017 to 24.57% in 2019 was driven exclusively by the expansion of the net profit margin, which more than offset the gradual decline in asset turnover. Conversely, the subsequent decline in ROA to 8.16% in 2022 was the result of a simultaneous compression in profit margins and historically low asset turnover, indicating a dual decline in both operational profitability and asset productivity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Four-Component Disaggregation of ROA

Abiomed Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Mar 31, 2022 8.16% = 0.72 × 1.00 × 18.47% × 0.62
Mar 31, 2021 15.09% = 0.78 × 1.00 × 34.01% × 0.57
Mar 31, 2020 16.69% = 0.79 × 1.00 × 30.54% × 0.69
Mar 31, 2019 24.57% = 0.98 × 1.00 × 34.23% × 0.73
Mar 31, 2018 14.26% = 0.70 × 1.00 × 27.07% × 0.76
Mar 31, 2017 9.47% = 0.57 × 1.00 × 20.59% × 0.81

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


Return on Assets (ROA) exhibited significant volatility over the six-year period, characterized by a strong ascent to a peak of 24.57% in March 2019, followed by a consistent decline to 8.16% by March 2022. The overall trajectory indicates that the drivers of profitability peaked in 2019 and have since faced systemic pressure.

Tax Burden
The tax burden ratio increased from 0.57 in 2017 to a peak of 0.98 in 2019, suggesting a period of improved tax efficiency or lower effective tax rates. However, this ratio subsequently declined to 0.72 by 2022, contributing to the overall reduction in net income relative to pre-tax profits.
Interest Burden
The interest burden remained constant at 1.00 across all reported years. This indicates that interest expenses did not reduce operating profits, signifying a capital structure with negligible or no interest-bearing debt during the period analyzed.
EBIT Margin
Operating profitability showed strong growth in the early part of the period, rising from 20.59% in 2017 to 34.23% in 2019. While the margin remained resilient through 2021, a sharp contraction occurred in 2022, falling to 18.47%, which represents the primary driver of the decline in ROA during the final year.
Asset Turnover
A persistent downward trend is observed in asset turnover, which declined steadily from 0.81 in 2017 to 0.62 in 2022. This consistent decrease suggests a diminishing efficiency in utilizing the asset base to generate sales revenue over the six-year duration.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Disaggregation of Net Profit Margin

Abiomed Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Mar 31, 2022 13.23% = 0.72 × 1.00 × 18.47%
Mar 31, 2021 26.61% = 0.78 × 1.00 × 34.01%
Mar 31, 2020 24.14% = 0.79 × 1.00 × 30.54%
Mar 31, 2019 33.66% = 0.98 × 1.00 × 34.23%
Mar 31, 2018 18.89% = 0.70 × 1.00 × 27.07%
Mar 31, 2017 11.70% = 0.57 × 1.00 × 20.59%

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The net profit margin exhibited a trajectory of expansion from 2017 through 2019, followed by a period of instability and a significant contraction by the end of the 2022 fiscal year.

EBIT Margin
Operating profitability demonstrated consistent growth from 20.59% in 2017 to a peak of 34.23% in 2019. Following this peak, the margin remained relatively resilient, hovering between 30% and 34% until 2021, before experiencing a sharp decline to 18.47% in 2022. This suggests a substantial reduction in operational efficiency or a significant increase in operating costs in the final year of the period.
Interest Burden
A constant ratio of 1.00 was maintained from 2017 through 2022. This indicates that interest expenses were negligible or non-existent, meaning that financing costs had no impact on the reduction of operating income to net income.
Tax Burden
The tax burden showed significant volatility, rising from 0.57 in 2017 to a peak of 0.98 in 2019, before gradually declining to 0.72 by 2022. The peak in 2019 indicates a period of high tax efficiency where a larger portion of pre-tax income was retained as net income.
Net Profit Margin Analysis
The fluctuations in the net profit margin were driven by the combined effects of operating performance and taxation. The maximum net profit margin achieved in 2019 (33.66%) resulted from the synchronization of the peak EBIT margin and the peak tax burden. The subsequent decline to 13.23% in 2022 was primarily precipitated by the collapse in the EBIT margin, as the tax burden remained relatively stable compared to the earliest periods of the analysis.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?